Core Viewpoint - The sales of Anjiahin® are expected to decline significantly by 2025 due to several factors, including medical insurance cost control and substantial price reductions initiated by the company in response to national healthcare policies [1] Group 1: Sales and Market Impact - The decline in Anjiahin® sales is primarily influenced by the reduction in patient usage resulting from medical insurance cost control measures [1] - Starting from the third quarter of 2025, Anjiahin® will undergo significant price cuts to align with the national healthcare bureau's initiatives, aiming to make the medication more accessible to patients [1] Group 2: Treatment Guidelines and Patient Care - The revised "Chinese Guidelines for Hemophilia Treatment (2025 Edition)" has redefined treatment approaches for coagulation disorders, shifting from traditional preventive treatment to regular replacement therapy and from on-demand treatment to temporary replacement therapy [1] - The medical community is emphasizing the importance of preventive treatment, and the company hopes that adult patients will receive similar protections as pediatric patients [1] - The company anticipates that the recombinant factor VIII will receive equal treatment as blood-derived factor VIII in the future [1]

（编辑 姚尧） 证券日报网讯 2月9日，红日药业在互动平台回答投资者提问时表示，公司高度重视投资者的诉求，公 司的信息披露工作是基于公平信息披露原则的合规操作。针对所涉事项目若尚未达到法定信息披露标 准，也未对公司生产经营，财务状况产生重大影响，公司无法在互动易平台进行答复。若在平台对未达 披露标准的事项进行证实或辟谣，将造成信息不对称，损害中小投资者的公平知情权，违背信息披露的 核心原则。公司始终对相关事项进展保持密切跟踪，若后续事项达到《上市公司信息披露管理办法》规 定的重大事项披露标准，将第一时间通过巨潮资讯网等指定信息披露渠道发布公告，确保所有投资者同 步获取信息。公司将坚守不断提升公司经营与创新能力的原则，以实际行动提升公司可持续盈利能力， 切实维护全体股东的合法权益。公司信息请以巨潮资讯网及深圳证券交易所发布的公告为准。 ...

Group 1 - The core viewpoint of the article highlights that the company, Funeng Technology, has secured multiple customer projects for its SPS products, including partnerships with major automotive manufacturers such as GAC, Geely, Jiangling, SANY Heavy Truck, and FAW Liberation [1] - The company reports that it has a sufficient backlog of orders and that the production capacity utilization rates at its Ganzhou and Guangzhou SPS bases are steadily increasing [1]

Core Viewpoint - The company is focusing on enhancing its product series and expanding into new application areas by collaborating with research institutions and responding to market demands [1] Group 1 - The company aims to achieve breakthroughs in fields such as life sciences, semiconductors, rare and precious metal separation and extraction, and nuclear-grade resins [1] - The company emphasizes its commitment to comply with relevant laws and regulations regarding information disclosure [1] - The company will announce any significant matters that meet disclosure standards in a timely manner [1]

（编辑 袁冠琳） 证券日报网讯 2月9日，立霸股份发布公告称，公司于近日收到由江苏省科学技术厅、江苏省财政厅、 国家税务总局江苏省税务局联合颁发的《高新技术企业证书》，证书编号为GR202532009078，发证时 间为2025年12月19日，有效期三年。 ...

Group 1 - The company, Green Eco, is considering the necessity and feasibility of purchasing directors and officers liability insurance based on industry practices and its own operational status [1] - The company emphasizes its commitment to strictly adhere to laws and regulations while safeguarding the legitimate rights and interests of all investors [1]

证券日报网讯 2月9日，吴通控股在互动平台回答投资者提问时表示，目前公司经营情况正常，具体经 营数据等内容敬请关注公司定期报告等相关公告。公司现将尚未使用的募集资金留存于募集资金专户， 并在保证不影响募投项目建设及确保资金安全的情况下，使用审议额度内的闲置募集资金进行现金管 理。后续如有相关事项达到披露标准，公司将及时履行信息披露义务。敬请投资者理性投资，注意风 险。 （编辑 楚丽君） ...

Core Viewpoint - Guanghua Co., Ltd. primarily focuses on polyester resin for powder coatings, which is a key raw material in the production of powder coatings widely used across various sectors such as construction materials, general industry, home appliances, furniture, automotive, and 3C products [1] Company Summary - The company does not typically engage directly with the end-users of powder coatings [1] - Investors can refer to the company's announcements for more detailed information [1]

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has achieved significant recognition in the field of vaccine research and development, particularly through its subsidiary Beijing Minhui Biological Technology Co., Ltd., which recently won the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2]. Group 1: Project Recognition - The project "Key Technology Innovation and Application for Rapid Confirmation and Precise Prevention of Emerging Viral Infectious Diseases" addresses critical challenges in the prevention and control of new viral infectious diseases [1]. - The project was led by the Jiangsu Provincial Center for Disease Control and Prevention and nominated by the Provincial Health Commission, highlighting the importance of collaboration in public health initiatives [1]. Group 2: Vaccine Development - Minhui Biological's independently developed inactivated virus vaccine platform is a core component of the project, receiving high recognition for its innovation, practicality, and scientific value [2]. - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent inactivated enterovirus vaccines, with the quadrivalent vaccine currently in Phase I clinical trials [2]. - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2]. Group 3: Strategic Implications - The recent award is seen as a validation of the company's commitment to independent innovation and its comprehensive strength in vaccine research and development, which is expected to enhance its core competitiveness and influence in the market [2]. - Successful development of these vaccines could further enrich the company's multi-valent vaccine portfolio, solidifying its market position and providing a strong foundation for sustainable growth [2].

Core Viewpoint - The company focuses on high-tech film sectors, emphasizing innovation in process technology and new product development [1] Group 1: Business Focus - The company is dedicated to the development of functional polyester films and optical films as its two main business areas [1] - The company employs a comprehensive control model encompassing "R&D + procurement + production + sales" to accurately meet market demands [1]